Immunome, Inc. (IMNM)
18.71
+0.80
(+4.50%)
USD |
NASDAQ |
Nov 06, 16:00
19.49
+0.78
(+4.17%)
After-Hours: 20:00
Immunome Research and Development Expense (Quarterly) : 59.88M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 59.88M |
| March 31, 2026 | 46.38M |
| December 31, 2025 | 50.77M |
| September 30, 2025 | 49.19M |
| June 30, 2025 | 40.45M |
| March 31, 2025 | 36.87M |
| December 31, 2024 | 47.30M |
| September 30, 2024 | 36.63M |
| June 30, 2024 | 34.72M |
| March 31, 2024 | 127.06M |
| December 31, 2023 | 90.18M |
| September 30, 2023 | 3.657M |
| June 30, 2023 | 5.559M |
| March 31, 2023 | 3.913M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.992M |
| September 30, 2022 | 5.111M |
| June 30, 2022 | 5.596M |
| March 31, 2022 | 7.942M |
| December 31, 2021 | 4.267M |
| September 30, 2021 | 4.227M |
| June 30, 2021 | 3.058M |
| March 31, 2021 | 1.803M |
| December 31, 2020 | 1.579M |
| September 30, 2020 | 1.467M |
| June 30, 2020 | 1.733M |
| March 31, 2020 | 1.952M |
| September 30, 2019 | 2.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Revolution Medicines, Inc. | 412.00M |
| Erasca, Inc. | 35.90M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |